Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor

References

• van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am. 1998;24:663–76.
   PubMed Web of Science ®Google Scholar
• Khan MA, Ball EJ. Genetic aspects of ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2002;16:675–90.
   PubMed Web of Science ®Google Scholar
• Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum. 1999;42: 2039–44.
   PubMed Web of Science ®Google Scholar
• Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800.
   PubMed Web of Science ®Google Scholar
• Pakozdi A, Amin MA, Haas CS, Martinez RJ, Haines GK 3rd, Santos LL, et al. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther. 2006;8:R132.
   Google Scholar
• Martinez A, Orozco G, Varade J, Sanchez Lopez M, Pascual D, Balsa A, et al. Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol. 2007;68:744–7.
   Google Scholar
• Willeke P, Gaubitz M, Schotte H, Maaser C, Domschke W, Schluter B, et al. Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjogren's syndrome. Arthritis Res Ther. 2007;9:R43.
   Web of Science ®Google Scholar
• Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus ery-thematosus. J Rheumatol. 2004;31:268–73.
   PubMed Web of Science ®Google Scholar
• Zou YQ, Lu LJ, Li SJ, Zeng T, Wang XD, Bao CD, et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease. Clin Biochem. 2008;41:519–24.
   PubMed Web of Science ®Google Scholar
• Antoniv TT, Ivashkiv LB. Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum. 2006;54:2711–21.
   PubMedGoogle Scholar
• Wu J, Cunha FQ, Liew FY, Weiser WY. IL-10 inhibits the synthesis of migration inhibitory factor and migration inhibitory factor-mediated macrophage activation. J Immunol. 1993;151: 4325–32.
   PubMed Web of Science ®Google Scholar
• Karakoc M, Altindag 0, Keles H, Soran N, Selek S. Serum oxidative-antioxidative status in patients with ankylosing spon-dylitis. Rheumatol Int. 2007;27:1131–4.
   Google Scholar
• Ozgocmen S, Sogut S, Ardicoglu 0, Fadillioglu E, Pekkutucu I, Akyol 0. Serum nitric oxide, catalase, superoxide dismutase, and malondialdehyde status in patients with ankylosing spondylitis. Rheumatol Int. 2004;24:80–3.
   Google Scholar
• Yazici C, Kose K, Calis M, Kuzuguden S, Kirnap M. Protein oxidation status in patients with ankylosing spondylitis. Rheu-matology (Oxford). 2004;43:1235–9.
   Google Scholar
• Horton JW. Free radicals and lipid peroxidation mediated injury in burn trauma: the role of antioxidant therapy. Toxicology. 2003;189:75–88.
   PubMed Web of Science ®Google Scholar
• LeGrand A, Fermor B, Fink C, Pisetsky DS, Weinberg JB, Vail TP, et al. Interleukin-1, tumor necrosis factor alpha, and inter-leukin-17 synergistically up-regulate nitric oxide and prosta-glandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum. 2001;44:2078–83.
   PubMed Web of Science ®Google Scholar
• Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D, Mom-cilovic M, Popadic D, Harhaji L, et al. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoim-mune diabetes mellitus. J Cell Physiol. 2008;215:665–75.
   Google Scholar
• Jong D, Murrell GA. Nitric oxide in arthritis. Free Radic Biol Med. 1998;24:1511–9.
   PubMed Web of Science ®Google Scholar
• Roberts S, Butler RC. Inflammatory mediators as potential ther-apeutic targets in the spine. Curr Drug Targets Inflamm Allergy. 2005;4:257–66.
   PubMedGoogle Scholar
• Pham TN, Rahman P, Tobin YM, Khraishi MM, Hamilton SF, Alderdice C, et al. Elevated serum nitric oxide levels in patients with inflammatory arthritis associated with co-expression of inducible nitric oxide synthase and protein kinase C-eta in peripheral blood monocyte-derived macrophages. J Rheumatol. 2003;30:2529–34.
   PubMed Web of Science ®Google Scholar
• Yang PT, Kasai H, Zhao LJ, Xiao WG, Tanabe F, Ito M. Increased CCR4 expression on circulating CD4(±) T cells in ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol. 2004;138:342–7.
   PubMed Web of Science ®Google Scholar
• van der Linden S, Valkenburg HA, Cats A. Evaluation of diag-nostic criteria for ankylosing spondylitis. A proposal for modi-fication of the New York criteria. Arthritis Rheum. 1984;27:361–8.
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Kawada K, Shimada T, Mori M. Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. Am J Obstet Gynecol. 1979;135:372–6.
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalvez JA, Garcia-Benayas C, Arenas J. Semiauto-mated measurement of nitrate in biological fluids. Clin Chem. 1998;44:679–81.
   PubMed Web of Science ®Google Scholar
• Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21: 1694–8.
   Google Scholar
• Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in anky-losing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.
   Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91.
   PubMed Web of Science ®Google Scholar
• Stojanovic I, Cvjeticanin T, Lazaroski S, Stosic-Grujicic S, Miljkovic D. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology. 2009;126: 74–83.
   Google Scholar
• Aeberli D, Leech M, Morand EF. Macrophage migration inhib-itory factor and glucocorticoid sensitivity. Rheumatology (Oxford). 2006;45:937–43.
   PubMedGoogle Scholar
• Aeberli D, Yang Y, Mansell A, Santos L, Leech M, Morand EF. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett. 2006; 580:974–81.
   PubMed Web of Science ®Google Scholar
• Chou CT, Huo AP, Chang HN, Tsai CY, Chen WS, Wang HP. Cytokine production from peripheral blood mononuclear cells in patients with ankylosing spondylitis and their first-degree rela-tives. Arch Med Res. 2007;38:190–5.
   PubMed Web of Science ®Google Scholar
• Goedecke V, Crane AM, Jaakkola E, Kaluza W, Laiho K, Weeks DE, et al. Interleukin 10 polymorphisms in ankylosing spondy-litis. Genes Immun. 2003;4:74–6.
   PubMed Web of Science ®Google Scholar
• Reikeras 0, HeIle A, Krohn CD, Brox JI. Systemic and local cytokine kinetics in musculoskeletal injury: a prospective study in patients with ankylosing spondylitis. Scand J Clin Lab Invest. 2008;22: 1–6.
   Google Scholar
• Stavitsky AB, Xianli J. In vitro and in vivo regulation by mac-rophage migration inhibitory factor (MIF) of expression of MHC-II, costimulatory, adhesion, receptor, and cytokine molecules. Cell Immunol. 2002;217:95–104.
   PubMed Web of Science ®Google Scholar
• Vazquez-Del MM, Garcia-Gonzalez A, Munoz-Valle JF, Garcia-Iglesias T, Martinez-Bonilla G, Bernard-Medina G, et al. Inter-leukin lbeta (IL- lbeta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol. 2002;29: 522–6.
   PubMed Web of Science ®Google Scholar
• Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 2005;52:3020–9.
   Google Scholar
• Morand EF. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J. 2005;35: 419–26.
   PubMed Web of Science ®Google Scholar
• Biasi D, Carletto A, Caramaschi P, Bellavite P, Andrioli G, Caraffi M, et al. Neutrophil functions, spondylarthropathies and HLA-B27: a study of 43 patients. Clin Exp Rheumatol. 1995;13: 623–7.
   PubMed Web of Science ®Google Scholar